🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the pathogen, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are increasing globally, with figures suggesting more than 82 million infections per year. Notably increased rates are reported in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely development in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted treatment choices presently on offer.”

Medical experts are deeply concerned about the increase in treatment-resistant strains. The WHO has listed it as a "critical concern". Ongoing monitoring showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in December for treating gonorrhoea. This disease can lead to major issues, including infertility. Researchers hope that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in close succession. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The charitable organization GARDP collaborated with the drug firm its industry partner to see it through.

“This approval signifies a huge turning point in the management of highly resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Global Access

According to data published in a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which uses two antibiotics. The study included nearly 1,000 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the ability to make available and distribute the drug in many developing nations.

Doctors treating patients have shared hope. Having a easy-to-administer therapy like this is described as a "game-changer" for gonorrhoea control. This is considered essential to reduce the burden of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.